Mylab partners with Thermo Fisher Scientific to launch RTPCR kits for infectious diseases in India

The kits have received licensing rights by the Central Drugs Standard Control Organisation (CDSCO)

Thermo Fisher Scientific and Mylab has announced a partnership to design and develop RTPCR kits for infectious diseases such as Multi-Drug Resistant Tuberculosis (MTB MDR), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and genetic analysis (HLA B27) and for other diseases of public health importance. The kits have received licensing rights by the Central Drugs Standard Control Organisation (CDSCO).

In India, TB, HIV and viral hepatitis are serious public health problems. Timely and accurate diagnosis is needed to achieve elimination of these diseases by 2030. In partnership with Thermo Fisher Scientific, the company aims to increase the access of the tests to a greater proportion of the population in India as well as world.

Hasmukh Rawal, Managing Director, Mylab Discovery Solutions said,  “Laboratories in India and globally rely on the innovative products from Thermo Fisher, now will also benefit with a much wider range of quality made-in-India diagnostic tests. Also, we would be assisting in tools for analysis of data to help labs make accurate results to their customers. With these test kits, we intend to help the government in meeting the elimination targets of these diseases.”

Jagjit Singh Anthak, Director, Genetic Sciences Group and Specialty Diagnostics Group, Thermo Fisher Scientific added, “Over the years, India has made significant progress in addressing infectious diseases such as Hepatitis B and C, HIV, and Tuberculosis. The country has implemented large-scale vaccination and treatment programs, as well as invested in research to better understand the epidemiology of these diseases and develop new diagnostic tools. However, India still faces challenges in controlling the spread of these diseases. At Thermo Fisher Scientific, we are committed to offering new innovations and workflows to advance research and diagnosis of these infections while actioning our mission, to enable our customers to make the world healthier, cleaner and safer.”

The Applied Biosystems TaqPath PCR kits by Thermo Fisher Scientific have been analytically and clinically validated for use in patient care for disease screening and diagnosis, monitoring of therapeutic response and disease progression, and identification of genetic risk factors.